Joseph Schachle
Directeur des opérations chez OCUPHIRE PHARMA, INC.
Fortune : 3 070 $ au 30/04/2024
Profil
Joseph K.
Schachle is currently the Director at Council for Entrepreneurial Development and the Chief Operating Officer at Ocuphire Pharma, Inc. He previously worked as the Marketing Director-Infectious Disease Products at MedImmune LLC, Marketing Director at GSK Plc, Chief Corporate Operations & Commercial Officer at Inspire Pharmaceuticals, Inc., Chief Operating Officer at Parion Sciences, Inc., Vice President-Strategy at MedThink Communications, Inc., and Chief Operating Officer at Opus Genetics, Inc. Mr. Schachle received his undergraduate degree from James Madison University and his MBA from Old Dominion University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCUPHIRE PHARMA, INC.
0,01% | 21/03/2024 | 2 000 ( 0,01% ) | 3 070 $ | 30/04/2024 |
Postes actifs de Joseph Schachle
| Sociétés | Poste | Début |
|---|---|---|
| OCUPHIRE PHARMA, INC. | Directeur des opérations | 27/11/2023 |
Council for Entrepreneurial Development
 Council for Entrepreneurial Development Miscellaneous Commercial ServicesCommercial Services Council for Entrepreneurial Development provides an interactive forum for entrepreneurs, investors, service professionals, academicians, researchers and public policy makers. Its services and programs include connections to capital, venture mentoring, and signature conferences empower member companies to go further. The company was founded in 1984 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Anciens postes connus de Joseph Schachle
| Sociétés | Poste | Fin |
|---|---|---|
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Directeur des opérations | 01/03/2023 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Sales & Marketing | 01/01/2003 |
| GSK PLC | Sales & Marketing | 01/04/2001 |
MedThink Communications, Inc.
 MedThink Communications, Inc. Advertising/Marketing ServicesCommercial Services MedThink Communications, Inc. is a healthcare communications agency that provides full-service offerings with focus on scientific and promotional communications. It offers scientific platform development, publication planning and execution and expert engagement services. The company was founded by Scott Goudy in 2004 and is headquartered in Raleigh, NC. | Corporate Officer/Principal | - |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Directeur des opérations | - |
Formation de Joseph Schachle
| James Madison University | Undergraduate Degree |
| Old Dominion University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GSK PLC | Health Technology |
| OCUPHIRE PHARMA, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Health Technology |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Commercial Services |
Council for Entrepreneurial Development
Council for Entrepreneurial Development Miscellaneous Commercial ServicesCommercial Services Council for Entrepreneurial Development provides an interactive forum for entrepreneurs, investors, service professionals, academicians, researchers and public policy makers. Its services and programs include connections to capital, venture mentoring, and signature conferences empower member companies to go further. The company was founded in 1984 and is headquartered in Durham, NC. | Commercial Services |
MedThink Communications, Inc.
MedThink Communications, Inc. Advertising/Marketing ServicesCommercial Services MedThink Communications, Inc. is a healthcare communications agency that provides full-service offerings with focus on scientific and promotional communications. It offers scientific platform development, publication planning and execution and expert engagement services. The company was founded by Scott Goudy in 2004 and is headquartered in Raleigh, NC. | Commercial Services |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
